N	Concordance
1	that a year of  treatment with 5-FU and levamisole is "moderately tolerable" in 
2	nsidered for adjuvant therapy with 5-FU/levamisole, with 5-FU/leucovorin, or  wi
3	at mediate resistance to the nematocide levamisole and to other cholinergic agon
4	g/kg on alternate days. The duration of levamisole therapy ranged from 6 to 31 m
5	fference. There were no side effects of levamisole therapy. Our findings suggest
6	UVEC) were cultured in the  presence of levamisole and examined by solid-phase e
7	vorin (25 mg/m2) supplemented with oral levamisole. Another 36 patients with or 
8	d with the standard 5-fluorouracil plus levamisole combination. The three-drug r
9	duction of remission with prednisolone, levamisole was administered at a dose of
10	 anism of action can yet be ascribed to levamisole in treating colon cancer, the
11	 esion molecules and determined whether levamisole could affect leukocyte adhesi
12	munopotentiation in late gestation with levamisole hydrochloride (0.5 mg/kg), vi